Danske Bank’s Neurocrine Biosciences NBIX Stock Holding History

Danske Bank’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.78M	Buy	52,095 +9,579	+23%	+$1.42M	0.02%	474
2026 Q1	$5.6M	Sell	42,516 -4,700	-10%	-$624K	0.01%	510
2025 Q4	$6.7M	Buy	47,216 +3,800	+9%	+$551K	0.02%	500
2025 Q3	$6.09M	Sell	43,416 -1,300	-3%	-$176K	0.02%	515
2025 Q2	$5.62M	Buy	44,716 +1,169	+3%	+$134K	0.01%	523
2025 Q1	$4.82M	Buy	43,547 +2,633	+6%	+$334K	0.01%	543
2024 Q4	$5.58M	Sell	40,914 -43,146	-51%	-$5.34M	0.02%	521
2024 Q3	$9.69M	Sell	84,060 -54,351	-39%	-$7.45M	0.03%	397
2024 Q2	$19.1M	Buy	138,411 +4,086	+3%	+$560K	0.07%	241
2024 Q1	$18.5M	Buy	+134,325	New	+$18.3M	0.06%	289

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

Danske Bank's NBIX Position: Q2 2026 in Review

Danske Bank increased its Neurocrine Biosciences (NBIX) stake by 23% in Q2 2026, buying an estimated $1.42M and bringing the position to 52,095 shares worth $8.78M. The position accounts for 0.02% of the portfolio, ranked #474.

Danske Bank first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. The position peaked at $19.1M in Q2 2024. 680 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

Danske Bank held 52,095 shares of Neurocrine Biosciences worth $8.78M as of Q2 2026.
Danske Bank bought 9,579 Neurocrine Biosciences shares in Q2 2026, an estimated $1.42M.
Neurocrine Biosciences made up 0.02% of Danske Bank's portfolio in Q2 2026, its #474 holding.
Danske Bank first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
Danske Bank's Neurocrine Biosciences position peaked at $19.1M in Q2 2024.
680 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Danske Bank's 13F filing for Q2 2026, filed 10 Aug 2026.